JP2013520446A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013520446A5 JP2013520446A5 JP2012554099A JP2012554099A JP2013520446A5 JP 2013520446 A5 JP2013520446 A5 JP 2013520446A5 JP 2012554099 A JP2012554099 A JP 2012554099A JP 2012554099 A JP2012554099 A JP 2012554099A JP 2013520446 A5 JP2013520446 A5 JP 2013520446A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- emp2
- composition according
- seq
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000003112 inhibitor Substances 0.000 claims 10
- 101710169959 Membrane protein 2 Proteins 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 201000002563 Histoplasmosis Diseases 0.000 claims 1
- 206010065630 Iris neovascularisation Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 201000002154 Pterygium Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30607310P | 2010-02-19 | 2010-02-19 | |
| US61/306,073 | 2010-02-19 | ||
| PCT/US2011/025772 WO2011103599A2 (en) | 2010-02-19 | 2011-02-22 | Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013520446A JP2013520446A (ja) | 2013-06-06 |
| JP2013520446A5 true JP2013520446A5 (enExample) | 2014-04-10 |
| JP5852968B2 JP5852968B2 (ja) | 2016-02-03 |
Family
ID=44483632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012554099A Expired - Fee Related JP5852968B2 (ja) | 2010-02-19 | 2011-02-22 | 上皮膜タンパク質２（ｅｍｐ２）結合試薬および眼疾患治療におけるその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20130034555A1 (enExample) |
| EP (1) | EP2536433B1 (enExample) |
| JP (1) | JP5852968B2 (enExample) |
| AU (1) | AU2011217785B2 (enExample) |
| CA (1) | CA2790500A1 (enExample) |
| WO (1) | WO2011103599A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2863986A1 (en) * | 2012-02-06 | 2013-08-15 | The Regents Of The University Of California | Emp2 regulates angiogenesis in cancer cells through induction of vegf |
| US10385395B2 (en) | 2012-04-11 | 2019-08-20 | The Regents Of The University Of California | Diagnostic tools for response to 6-thiopurine therapy |
| JP6533078B2 (ja) * | 2015-03-20 | 2019-06-19 | テルモ株式会社 | 画像診断装置、その制御方法、プログラム及びコンピュータ可読記憶媒体 |
| IL278246B1 (en) * | 2018-04-30 | 2025-10-01 | The Usa As Represented By The Secretary Dept Of Health And Human Services | Using factors that target epithelial membrane protein 2 to treat lung disorders |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5264188A (en) | 1991-01-22 | 1993-11-23 | Phillips Petroleum Company | Multi-stage hydrotreating process and apparatus |
| US6413245B1 (en) | 1999-10-21 | 2002-07-02 | Alcon Universal Ltd. | Sub-tenon drug delivery |
| GB0004212D0 (en) | 2000-02-23 | 2000-04-12 | Plexus Ocean Syst Ltd | Pipe joint |
| PL223153B1 (pl) | 2002-09-18 | 2016-10-31 | Allergan Inc | Urządzenie do wszczepiania implantu okulistycznego |
| EP1583550A2 (en) | 2003-01-16 | 2005-10-12 | D. Collen Research Foundation vzw | Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia |
| US20090148527A1 (en) | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| US20060182783A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| WO2005110374A1 (en) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US8648052B2 (en) * | 2005-04-15 | 2014-02-11 | The Regents Of The University Of California | Prevention of chlamydia infection using SIRNA |
| KR20080106946A (ko) * | 2006-03-29 | 2008-12-09 | 제넨테크, 인크. | 종양의 진단 및 치료 |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| US20090081277A1 (en) | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Pharmaceutical formulations and methods for treating ocular conditions |
| JP5911805B2 (ja) * | 2009-11-20 | 2016-04-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ） |
-
2011
- 2011-02-22 WO PCT/US2011/025772 patent/WO2011103599A2/en not_active Ceased
- 2011-02-22 JP JP2012554099A patent/JP5852968B2/ja not_active Expired - Fee Related
- 2011-02-22 AU AU2011217785A patent/AU2011217785B2/en not_active Ceased
- 2011-02-22 US US13/580,100 patent/US20130034555A1/en not_active Abandoned
- 2011-02-22 EP EP11745457.9A patent/EP2536433B1/en not_active Not-in-force
- 2011-02-22 CA CA2790500A patent/CA2790500A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014113046A (ru) | Профилактика и лечение патологических состояний глаз, вызванных комплементом | |
| RU2014129316A (ru) | Способы ингибирования глазного ангиогенеза | |
| JP2020114218A5 (enExample) | ||
| JP2010528047A5 (enExample) | ||
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| JP2016504416A5 (enExample) | ||
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20211453A1 (es) | Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina | |
| JP2012165745A5 (enExample) | ||
| RU2015121755A (ru) | Антагонисты ил-6 и их применение | |
| HRP20211641T1 (hr) | Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti | |
| RU2009149385A (ru) | АНТИТЕЛА ПРОТИВ С3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ | |
| MY176514A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| AR110719A1 (es) | Anticuerpos humanos a la toxina hemolisina a de s. aureus | |
| JP2015514110A5 (enExample) | ||
| BR112013030958B1 (pt) | Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo | |
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| JP2017515811A5 (enExample) | ||
| AR102592A1 (es) | Anticuerpos biespecíficos y métodos de uso en oftalmología | |
| JP2014519334A5 (enExample) | ||
| JP2018527327A5 (enExample) | ||
| IL310376A (en) | Methods and preparations for the treatment of angiogenic disorders using anti-VEGF agents | |
| RU2017120361A (ru) | Антитела к pdgf-b и способы их применения | |
| JP2013520446A5 (enExample) | ||
| RU2018145017A (ru) | Применение сиролимуса для лечения экссудативной возрастной макулярной дегенерации с персистирующим отеком |